drugset / Trial / NCT00205816

Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.

NCT00205816

Phase 3 Completed 26 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations. The secondary objective is to evaluate the safety and efficacy of tigecycline in the treatment of patients with selected serious infections where other treatment has not been successful.

Timeline

Start
2004-01
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tigecycline Small molecule